Cargando…

KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer

Detalles Bibliográficos
Autor principal:	Pacheco, Jose M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082291/ https://www.ncbi.nlm.nih.gov/pubmed/32206562 http://dx.doi.org/10.21037/tlcr.2020.01.12

Ejemplares similares

KEYNOTE-407: new hope for the treatment of lung squamous cell carcinoma
por: Zhao, Xinmin, et al.
Publicado: (2020)

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
por: Viteri, Santiago, et al.
Publicado: (2020)

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
por: Chen, Hao, et al.
Publicado: (2023)

Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study
por: Gómez-Randulfe, Igor, et al.
Publicado: (2023)

Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non‐small‐cell lung cancer in KEYNOTE‐407
por: Sugawara, Shunichi, et al.
Publicado: (2023)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
por: Cheng, Ying, et al.
Publicado: (2021)

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
por: Novello, Silvia, et al.
Publicado: (2023)

The KEYNOTE-189 trial as a new paradigm making cure a reality for metastatic non-squamous non-small cell lung cancer
por: Wang, Yanye, et al.
Publicado: (2020)

Considerations for adjuvant immunotherapy in stage II melanoma: KEYNOTE-716 and beyond
por: Chen, Lanyi Nora, et al.
Publicado: (2023)

Surgery for stage IV non-small cell lung cancer?
por: Puig, Carlos A., et al.
Publicado: (2020)

Translating KEYNOTE-048 into practice recommendations for head and neck cancer
por: Szturz, Petr, et al.
Publicado: (2020)

Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition
por: de Silva, Madhawa, et al.
Publicado: (2020)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Vaccine safety concerns: Should we be changing the way we support immunization?
por: MacDonald, Noni E, et al.
Publicado: (2020)

Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
por: Li, Fengtan, et al.
Publicado: (2021)

Long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the KEYNOTE-048 trial
por: Sano, Daisuke, et al.
Publicado: (2023)

How we should tailor the nodal staging for various types of lung cancer?
por: Watanabe, Shun-ichi
Publicado: (2020)

Should we keep on doing robotic surgery to treat lung cancer in 2020?
por: Montagne, François, et al.
Publicado: (2020)

Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
por: Borcoman, Edith, et al.
Publicado: (2020)

It is time to change the way we manage mild asthma: an update in GINA 2019
por: Muneswarao, Jaya, et al.
Publicado: (2019)

Anti-PDL1 effect in squamous non-small cell lung cancer
por: Rahouma, Mohamed, et al.
Publicado: (2020)

Surgery for early-stage small cell lung cancer: is it worth it?
por: Vyfhuis, Melissa A. L., et al.
Publicado: (2019)

Keynotes
Publicado: (2023)

Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)
por: Pai, Sara I., et al.
Publicado: (2019)

Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
por: Russo, Alessandro, et al.
Publicado: (2019)

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
por: Yellala, Amulya, et al.
Publicado: (2020)

First-line management of advanced non-small-cell lung cancer: can we do better?
por: Chouaïd, Christos, et al.
Publicado: (2023)

A new movie is about to premiere in nearby theaters. The way we see and treat obesity is bound to change
por: Friedman, Rogério
Publicado: (2022)

Different segments different survival for T1N0 non-small cell lung cancer: should we change our paradigm in patients with superior segment tumors?
por: Minervini, Fabrizio, et al.
Publicado: (2021)

Radiotherapy tumor volume for limited-stage small cell lung cancer: less is more
por: Levy, Antonin, et al.
Publicado: (2020)

Neoadjuvant therapy in localized non-small cell lung cancer: can we do better than chemotherapy?
por: Chau, Brittney, et al.
Publicado: (2019)

Keynote Address
por: Zinsou, Lionel
Publicado: (2019)

Keynote Address
por: Cherkaoui El Moursli, Rajaa
Publicado: (2019)

Keynote Address
por: Schönenberger, Klaus
Publicado: (2019)

Welcome & Keynote
por: Martin, Robert "Uncle Bob"
Publicado: (2019)

Keynote Address
por: Bordry, Frederick
Publicado: (2019)

Keynote presentations
por: Desai, Nitin, et al.
Publicado: (2004)

Keynote Lectures
Publicado: (2004)

Keynote Lecture
Publicado: (2017)

KEYNOTE ADDRESS
por: Fenner, Frank
Publicado: (1986)

Cannot write session to /tmp/vufind_sessions/sess_2bnf6m3h2ndhliton867cs5384